Search

Societal Impact Statement: Rice wild relatives (RWR) provide valuable genetic resources for modern rice breeding, yet knowledge gaps constrain their conservation and further utilization. To address these gaps, the potential distributions of 22 RWR taxa were modeled, and their conservation statuses were assessed. Most taxa were identified as medium priority for further conservation. Further ex‐situ collecting hotspots are in Southeast and South Asia, Northern Australia, West Africa, and tropical Americas, while habitat protection lies in Southeast and South Asia, Northern Australia, and West Africa. Climate change may shift equatorial habitats to higher latitudes and mountain habitats to higher altitudes. Summary: Rice wild relatives (RWR) provide valuable genetic resources for modern rice breeding. However, knowledge gaps on their geographic distributions and conservation status constrain their conservation and further utilization.To fill these critical gaps, we modeled the potential distributions of 22 RWR taxa under current climate scenarios, assessed their conservation status, both ex situ (in genebanks or botanical gardens) and in situ (in protected areas), and examined changes in taxa richness of RWR in predicted areas under future climate scenarios.The RWR were primarily distributed in tropical Asia to tropical Australia, tropical Africa, and South and Central America. We identified 4 out of 22 taxa as high priority (HP) for further conservation action and 18 taxa as medium priority (MP).Hotspots requiring further collecting for ex situ conservation are concentrated in Southeast and South Asia, Northern Australia, West Africa, and tropical Americas. Meanwhile, habitat protection should be enhanced in Southeast and South Asia, Northern Australia, and West Africa. Under future climate change, suitable habitats near the equator are expected to shift toward higher latitudes and some in lower‐latitude basins may become unsuitable due to excessive heat, resulting in decreased taxa richness in these areas. Additionally, suitable habitats in high mountain areas may shift to higher altitudes, potentially augmenting taxa richness in the highlands. Our findings provide vital insights to guide future rescue conservation efforts for RWR. [ABSTRACT FROM AUTHOR]

In order to have a real‐world experience in the "METAVERSE", an ultra‐high PPI device is urgently needed. In this paper, we proposed a 2117‐PPI Fast LCD Device with LTPO and Color Filter On Array (COA) technologies. We used real RGB with higher physical resolution instead of Sub Pixel Rendering (SPR) technology. We adopted the "Smart BM" technology to reduce the Screen Door Effect and the Electric Field Enhancement (EFE) technology to enhance the LC efficiency. We have developed the Planarization (PLN) Hole Filling (PHF) technology which can both increase LC efficiency and reduce the dark state light leakage. At the same time, we also used the "Smart BM" technology to improve CR. [ABSTRACT FROM AUTHOR]

The role of rice genomics in breeding progress is becoming increasingly important. Deeper research into the rice genome will contribute to the identification and utilization of outstanding functional genes, enriching the diversity and genetic basis of breeding materials and meeting the diverse demands for various improvements. Here, we review the significant contributions of rice genomics research to breeding progress over the last 25 years, discussing the profound impact of genomics on rice genome sequencing, functional gene exploration, and novel breeding methods, and we provide valuable insights for future research and breeding practices. [ABSTRACT FROM AUTHOR]

Vocabulary learning and teaching has been one of the main issues in ESL/EFL learning and teaching research. EFL teachers in China, in particular, are grappling with the effective vocabulary teaching methods. This paper is doing part of this job in a different way. It discusses three principles based on Cognitive Linguistics (CL), namely the study of categorization, prototype, and metaphor, and implications of these principles in formal vocabulary instruction in a Chinese context of English learning in South-western mainland China.

Recruitment and accumulation of reactive astrocytes around senile plaques are common pathological features of Alzheimer's disease (AD), with unclear mechanisms. Chemerin, an adipokine implicated in neuroinflammation, acts through its receptor, chemokine-like receptor 1 (CMKLR1), which also functions as a receptor for amyloid β (Aβ). The impact of the chemerin/CMKLR1 axis on astrocyte migration towards Aβ plaques is unknown. Here we investigated the effect of CMKLR1 on astrocyte migration around Aβ deposition in APP/PS1 mice with Cmklr1 knockout (APP/PS1-Cmklr1−/−). CMKLR1-expressed astrocytes were upregulated in the cortices and hippocampi of 9-month-old APP/PS1 mice. Chemerin mainly co-localized with neurons, and its expression was reduced in the brains of APP/PS1 mice, compared to WT mice. CMKLR1 deficiency decreased astrocyte colocalization with Aβ plaques in APP/PS1-Cmklr1−/− mice, compared to APP/PS1 mice. Activation of the chemerin/CMKLR1 axis promoted the migration of primary cultured astrocytes and U251 cells, and reduced astrocyte clustering induced by Aβ42. Mechanistic studies revealed that chemerin/CMKLR1 activation induced STING phosphorylation. Deletion of STING attenuated the promotion of the chemerin/CMKLR1 axis relative to astrocyte migration and abolished the inhibitory effect of chemerin on Aβ42-induced astrocyte clustering. These findings suggest the involvement of the chemerin/CMKLR1/STING pathway in the regulation of astrocyte migration and recruitment to Aβ plaques/Aβ42. [ABSTRACT FROM AUTHOR]

For sustainable application of chloroprene rubber (CR), a new technology is developed by the vulcanization of CR using 2,2'-dithiodipyridine (DPD) as a cross-linking agent with the reprocessing performance owing to disulfide metathesis. When DPD was incorporated into CR vulcanization, the Menschutkin reaction between allyl chloride group and pyridine group occurred with a maximum exothermic peak at 184°C. The number of effective cross-linking bond at 0.5 phr DPD vulcanizate was higher than that at high DPD content. This vulcanizate showed high tensile strength (11.12 MPa) and elongation at break (1253 ± 120%) owing to the exchangeable disulfide bond in the system. Under the catalysis of triphenylphosphine, the metathesis of disulfide compound was improved obviously, which endowed CR/DPD vulcanizates with good recyclability performance. Disulfide cross-linkage maintains its stability at low temperature, thus ensuring the mechanical stability of CR/DPD vulcanizate under the ambient conditions. Vulcanization and reprocessing of CR/DPD vulcanizate can be conducted with common industrial rubber processing equipment. Such reprocessable chloroprene rubber could have potential application in CR industry, also serve to significantly improve environmental sustainability. [ABSTRACT FROM AUTHOR]

Aims: To investigate the impact of AdipoQ polymorphisms, and their additional interactions with smoking and drinking on coronary heart disease (CHD) risk based on Chinese population. Methods: Hardy‒Weinberg equilibrium (HWE) was performed using SNPStats (available online at http://bioinfo.iconcologia.net/SNPstats). Generalized multifactor dimensionality reduction (GMDR) model was used to screen the best gene‒gene and gene‒environment interaction combinations. Logistic regression was performed to investigate association between four single-nucleotide polymorphisms (SNPs) and CHD and the interaction effect between rs1501299 and smoking. Results: Logistic analysis showed that CHD risks were higher in carriers with homozygous mutant of rs1501299 and rs2241766 than those with wild-type homozygotes, odds ratio (ORs) (95%CI) were 1.49 (1.19–1.95) and 1.71 (1.33–2.24), respectively, but CHD risks were lower in carriers with homozygous mutant of rs7649121 than those with wild-type homozygotes, OR (95%CI) was 0.72 (0.51–0.96). GMDR model indicated that there was a significant two-locus model (p = 0.0107) involving rs1501299 and current smoking, indicating a potential gene–environment interaction between rs1501299 and current smoking. Overall, the cross-validation consistency of this model was 9/10, and the testing accuracy was 60.11% (p = 0.0010). T-allele carriage had 42% prevalence, and one-quarter of them were current smokers. Smokers with rs1501299-GT or TT genotype have the highest CHD risk, compared to never-smokers with rs1501299-GG genotype, OR (95%CI) was 3.56 (1.91–5.42), after adjustment for gender, age, alcohol status, and body mass index. But we did not find any significant gene–gene and gene–drinking interaction combinations in GMDR models. Conclusions: Polymorphisms in rs1501299 and rs2241766, and their additional interactions between rs1501299 and smoking were associated with increased CHD risks: polymorphism in rs7649121 was associated with decreased CHD risks.

Introduction. Despite the availability of effective biologic therapies for psoriasis, there is no gold-standard treatment for nonpustular palmoplantar psoriasis (ppPsO). Methods. G-PLUS, a phase IIIb, double-blind, placebo-controlled, multicentre clinical trial, randomised adults with moderate-to-severe nonpustular ppPsO and limited plaque psoriasis (Psoriasis Area and Severity Index (PASI) ≥3 but <10) to guselkumab (an interleukin-23p19 blocker) or placebo. Placebo participants were crossed over to receive guselkumab at week (Wk) 16. The primary efficacy endpoint was the proportion of participants achieving palmoplantar PASI (ppPASI) 75 response at Wk16; clinical, biomarker, and quality-of-life endpoints were assessed through Wk48 and safety through Wk56. Results. At Wk16, ppPASI75 response was achieved by 35.9% of the guselkumab participants compared with 28.2% in the placebo group, resulting in a 7.7% difference in response rates (95% confidence interval: −11.5 and 24.7), which was not statistically significant (p = 0.533). More pronounced numerical improvements favouring guselkumab were observed for more stringent efficacy endpoints, such as Wk16 palmoplantar Investigator's Global Assessment (ppIGA) 0/1 response (guselkumab 34.6% vs. placebo 15.4%). Through Wk48, further improvements were observed in ppPASI75 response (55.1% and 64.1%) and ppIGA 0/1 response (42.3% and 48.7%) for the guselkumab and placebo-crossover groups, respectively. Dermatology Life Quality Index responses showed comparable trends at both timepoints. Safety and pharmacodynamic findings were consistent with the established profile for guselkumab. Serum biomarker levels were significantly reduced with guselkumab and correlated with the baseline PASI score but not the ppPASI score. Conclusion. Although the primary endpoint was not met, analysis of stringent secondary endpoints and post hoc analyses showed numerical improvements favouring guselkumab at Wk16. There were no new safety signals. Further studies are warranted to better understand the impact of guselkumab treatment in patients with ppPsO. This trial is registered with NCT03998683. [ABSTRACT FROM AUTHOR]

Mycobacterium marseillense is a member of the M. avium complex (1) that has caused infections with lymphatic or pulmonary involvement sporadically in humans (2-4). We report M. marseillense infection involving [...]

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that causes substantial physical, emotional and psychological burdens. Guselkumab, a monoclonal antibody that binds to the p19 subunit of interleukin‐23, has demonstrated high levels of efficacy in the treatment of inflammatory diseases, including psoriasis and psoriatic arthritis. Objective: To evaluate the effect of guselkumab on the treatment of HS, a phase 2, multicentre, randomized, placebo‐controlled, double‐blind, proof‐of‐concept study was conducted. Methods: Patients ≥18 years of age with moderate‐to‐severe HS for ≥1 year were randomized to (1) guselkumab 200 mg by subcutaneous (SC) injection every 4 weeks (q4w) through Week 36 (guselkumab SC); (2) guselkumab 1200 mg intravenously (IV) q4w for 12 weeks, then switched to guselkumab 200 mg SC q4w from Weeks 12 through 36 (guselkumab IV); or (3) placebo for 12 weeks, with re‐randomization to guselkumab 200 mg SC q4w at Weeks 16 through 36 (placebo → guselkumab 200 mg) or guselkumab 100 mg SC at Weeks 16, 20, 28 and 36 and placebo at Weeks 24 and 32 (placebo → guselkumab 100 mg). End points included HS clinical response (HiSCR) and patient‐reported outcomes. Results: Although guselkumab SC or guselkumab IV resulted in numerically higher HiSCR versus placebo at Week 16 (50.8%, 45.0%, 38.7%, respectively), statistical significance was not achieved. Numerically greater improvements in patient‐reported outcomes were also observed for guselkumab SC and guselkumab IV versus placebo at Week 16. Through Week 40, no clear differences to suggest a dose response were observed for HiSCR and patient‐reported outcomes. Conclusions: Despite modest improvements, the primary end point was not met and the overall findings do not support the efficacy of guselkumab in the treatment of HS. Clinicaltrials.gov: NCT 03628924. [ABSTRACT FROM AUTHOR]

Background The effectiveness of available biologics for the treatment of hidradenitis suppurativa (HS) is limited. Additional therapeutic options are needed. Objectives To investigate the efficacy and mode of action of guselkumab [an anti-interleukin (IL)-23p19 monoclonal antibody] 200 mg subcutaneously every 4 weeks for 16 weeks in patients with HS. Methods An open-label, multicentre, phase IIa trial in patients with moderate-to-severe HS was carried out (NCT04061395). The pharmacodynamic response in skin and blood was measured after 16 weeks of treatment. Clinical efficacy was assessed using the Hidradenitis Suppurativa Clinical Response (HiSCR), the International Hidradenitis Suppurativa Severity Score System (IHS4), and the abscess and inflammatory nodule (AN) count. The protocol was reviewed and approved by the local institutional review board (METC 2018/694), and the study was conducted in accordance with good clinical practice guidelines and applicable regulatory requirements. Results Thirteen of 20 patients (65%) achieved HiSCR with a statistically significant decrease in median IHS4 score (from 8.5 to 5.0; P = 0.002) and median AN count (from 6.5 to 4.0; P = 0.002). The overall patient-reported outcomes did not show a similar trend. One serious adverse event, likely to be unrelated to guselkumab treatment, was observed. In lesional skin, transcriptomic analysis revealed the upregulation of various genes associated with inflammation, including immunoglobulins, S100, matrix metalloproteinases, keratin, B-cell and complement genes, which decreased in clinical responders after treatment. Immunohistochemistry revealed a marked decrease in inflammatory markers in clinical responders at week 16. Conclusions Sixty-five per cent of patients with moderate-to-severe HS achieved HiSCR after 16 weeks of treatment with guselkumab. We could not demonstrate a consistent correlation between gene and protein expression and clinical responses. The main limitations of this study were the small sample size and absence of a placebo arm. The large placebo-controlled phase IIb NOVA trial for guselkumab in patients with HS reported a lower HiSCR response of 45.0–50.8% in the treatment group and 38.7% in the placebo group. Guselkumab seems only to be of benefit in a subgroup of patients with HS, indicating that the IL-23/T helper 17 axis is not central to the pathophysiology of HS. [ABSTRACT FROM AUTHOR]